AbbVie has agreed to acquire Aliada Therapeutics for $1.4 billion, gaining access to innovative drug delivery technology aimed at overcoming the blood-brain barrier and a clinical-stage Alzheimer’s treatment, ALIA-1758. This move aligns with AbbVie’s focus on neuroscience, enhancing its capabilities in developing therapies for neurological disorders. The deal is expected to close by year-end and reflects a strategic investment in a sector facing challenges but also potential breakthroughs.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
